Insmed slips as investors weigh recent analyst caution and launch expectations

Insmed Incorporated (INSM) is down 3.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be continued pressure from a recent analyst price-target cut and broader investor concern that second-quarter performance for BRINSUPRI will need to justify Insmed’s still-rich growth expectations. There does not appear to be a major new company-specific negative announcement today, so the move looks tied more to sentiment, valuation, and positioning than to a fresh operational setback.

Details:

A recent analyst note lowered the stock’s price target while keeping a positive rating, citing volatility and heavier investor focus on upcoming second-quarter results for BRINSUPRI.

Insmed’s first-quarter update was fundamentally strong, with total revenue of $306.0 million and BRINSUPRI revenue of $207.9 million, but management kept its 2026 BRINSUPRI outlook at at least $1 billion rather than raising guidance.

The company’s investor relations page shows no major adverse press release since early June, suggesting today’s decline is not obviously tied to a new trial miss, regulatory setback, or earnings warning.

An SEC filing in May registered an indeterminate amount of future debt securities and common stock under a Form S-3 shelf, which can add a financing overhang even when no immediate capital raise is announced.

Sources:

Insmed Investor Relations, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INSM Insider Trading Activity

$INSM insiders have traded $INSM stock on the open market 115 times in the past 6 months. Of those trades, 0 have been purchases and 115 have been sales.

Here’s a breakdown of recent trading of $INSM stock by insiders over the last 6 months:

WILLIAM LEWIS (Chair and CEO) has made 0 purchases and 60 sales selling 183,855 shares for an estimated $25,989,404.
ROGER ADSETT (Chief Operating Officer) has made 0 purchases and 9 sales selling 101,348 shares for an estimated $16,288,414.
MARTINA M.D. FLAMMER (Chief Medical Officer) has made 0 purchases and 29 sales selling 76,072 shares for an estimated $10,711,513.
MICHAEL ALEXANDER SMITH (Chief Legal Officer) has made 0 purchases and 11 sales selling 60,627 shares for an estimated $8,838,775.
SARA BONSTEIN (Chief Financial Officer) has made 0 purchases and 6 sales selling 16,066 shares for an estimated $2,132,573.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$INSM Hedge Fund Activity

We have seen 378 institutional investors add shares of $INSM stock to their portfolio, and 364 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DARWIN GLOBAL MANAGEMENT, LTD. removed 4,128,093 shares (-19.7%) from their portfolio in Q1 2026, for an estimated $675,025,767
FMR LLC added 3,232,231 shares (+32.6%) to their portfolio in Q1 2026, for an estimated $528,534,413
ORBIS ALLAN GRAY LTD removed 2,307,133 shares (-55.2%) from their portfolio in Q1 2026, for an estimated $377,262,388
ARTISAN PARTNERS LIMITED PARTNERSHIP added 1,683,552 shares (+34.8%) to their portfolio in Q1 2026, for an estimated $275,294,423
BLACKROCK, INC. added 1,613,094 shares (+10.7%) to their portfolio in Q1 2026, for an estimated $263,773,130
CAPITAL WORLD INVESTORS added 1,362,291 shares (+inf%) to their portfolio in Q1 2026, for an estimated $222,761,824
D. E. SHAW & CO., INC. removed 1,306,469 shares (-23.1%) from their portfolio in Q4 2025, for an estimated $227,377,864

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$INSM Analyst Ratings

Wall Street analysts have issued reports on $INSM in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 02/23/2026
UBS issued a "Buy" rating on 01/06/2026

To track analyst ratings and price targets for $INSM, check out Quiver Quantitative's $INSM forecast page.

$INSM Price Targets

Multiple analysts have issued price targets for $INSM recently. We have seen 15 analysts offer price targets for $INSM in the last 6 months, with a median target of $212.0.

Here are some recent targets:

Jessica Fye from JP Morgan set a target price of $179.0 on 06/08/2026
Leonid Timashev from RBC Capital set a target price of $195.0 on 06/05/2026
Danielle Brill from Truist Securities set a target price of $185.0 on 05/14/2026
Benjamin Burnett from Wells Fargo set a target price of $160.0 on 05/08/2026
Vamil Divan from Guggenheim set a target price of $226.0 on 05/08/2026
Adam Walsh from Roth Capital set a target price of $212.0 on 04/17/2026
Eliana Merle from Barclays set a target price of $237.0 on 04/01/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.